Literature DB >> 12706290

5'Deiodinase in two breast cancer cell lines: effect of triiodothyronine, isoproterenol and retinoids.

Pablo García-Solís1, Carmen Aceves.   

Abstract

Thyroid hormones participate in the regulation of growth, development and energy expenditure of vertebrates. Type I (D1) and type II 5'deiodinases catalyze the peripheral conversion of the thyroid prohormone thyroxine to the active form triiodothyronine (T3). D1 is expressed in organs like liver, thyroid, and lactating mammary gland. This enzyme is regulated in an organ-specific manner by a wide number of factors like carbohydrates, T3, thyrotropin, and catecholamines. However, it has been shown that in several types of cancer the expression of D1 is reduced, lost, or regulated by different components. In the present work we describe the expression and regulation of 5'deiodinases in two breast cancer cell lines: MCF-7 (ovarian hormone-dependent) and MDA-MB-231 (ovarian hormone-independent). Our results showed that MCF-7 cells expressed D1 activity ( approximately 10 pmol I(-)/mg protein per h), which was stimulated only by retinoic acid treatments, but not by T3 or the beta-adrenergic agonist isoproterenol. In MDA-MB-231 cells, deiodinase activity was not detected in control conditions nor under any of these treatments. These results support the notion that D1 expression could represent a sensitive differentiation marker.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706290     DOI: 10.1016/s0303-7207(03)00007-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Causal associations of autoimmune thyroiditis and papillary thyroid carcinoma: mRNA expression of selected nuclear receptors and other molecular targets.

Authors:  Dana Macejova; Jan Podoba; Lucia Toporova; Marianna Grigerova; Karol Kajo; Katarina Machalekova; Julius Brtko
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

Review 2.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

Review 3.  Is iodine a gatekeeper of the integrity of the mammary gland?

Authors:  Carmen Aceves; Brenda Anguiano; Guadalupe Delgado
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-04       Impact factor: 2.673

4.  Effects of chronic retinoid administration on pituitary function.

Authors:  A R Angioni; A Lania; A Cattaneo; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

5.  MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer.

Authors:  Joanna Boguslawska; Anna Wojcicka; Agnieszka Piekielko-Witkowska; Adam Master; Alicja Nauman
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

6.  Thyroid hormone deiodinases and cancer.

Authors:  Sabina Casula; Antonio C Bianco
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-01       Impact factor: 5.555

7.  Enzymatic activity of type 1 iodothyronine deiodinase in selected liver tumors.

Authors:  Oskar Kornasiewicz; Marcin Dębski; Michal Grat; Barbara Lenartowicz; Marta Stępnowska; Anna Szałas; Ewa Bar-Andziak; Marek Krawczyk
Journal:  Arch Med Sci       Date:  2013-08-20       Impact factor: 3.318

Review 8.  Deiodinases and Cancer.

Authors:  Annarita Nappi; Maria Angela De Stefano; Monica Dentice; Domenico Salvatore
Journal:  Endocrinology       Date:  2021-04-01       Impact factor: 4.736

Review 9.  The TSH/Thyroid Hormones Axis and Breast Cancer.

Authors:  Ioannis A Voutsadakis
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

10.  The enzymatic activity of type 1 iodothyronine deiodinase (D1) is low in liver hemangioma: a preliminary study.

Authors:  Oskar Kornasiewicz; Marcin Debski; Marta Stepnowska; Anna Szałas; Ewa Bar-Andziak; Marek Krawczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-01-05       Impact factor: 4.291

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.